An established drug for recurrent multiple myeloma might effectively be repurposed to improve the survival and day-to-day lives of patients with devastating sickle cell disease, according to revealing new research by a Feinstein Institute for Medical Research scientist.
The study, by Lionel Blanc, PhD, an assistant investigator at the Feinstein Institute, will be published Dec. 17 in the journal Blood. Dr. Blanc’s research, performed in collaboration with the New York Blood Center, Yale School of Medicine and University of Montpellier in France, was the first to identify how the drug pomalidomide increases production of fetal hemoglobin, known to interfere with the so-called “sickling” of red blood cells implicated in sickle cell disease (SCD).
Illuminating pomalidomide’s mechanism of action offers proof of concept that the US Food and Drug Administration (FDA)-approved medication could potentially be used to treat SCD, representing better outcomes compared to current drug treatment for the 100,000 Americans with SCD, an inherited disorder causing poor oxygen delivery, organ damage and even death.
“We knew the drug would make fetal hemoglobin, but we didn’t know to what extent or how. That was the goal of the study,” explained Dr. Blanc, also an assistant professor of molecular medicine and pediatrics at Hofstra North Shore-LIJ School of Medicine and an Allied World St. Baldrick’s Scholar.
“We can also say something else – that hydroxyurea, the only FDA-approved drug for sickle cell anemia, was less effective than pomalidomide and appeared to act through a different mechanism of action,” he added. “The current therapy is good, but not everyone responds equally to hydroxyurea, and what we hope with pomalidomide is to improve this.”
Pomalidomide, a derivative of thalidomide used in advanced cases of the cancer multiple myeloma, works by killing malignant plasma cells. But Dr. Blanc and his colleagues demonstrated in the new research, performed on stem cells taken from five SCD patients and 120 normal controls, how pomalidomide also generated fetal hemoglobin, the fetal version of the protein in red blood cells that carries oxygen to body tissues.
In patients with congenital conditions producing anemia such as SCD and beta-thalassemia, fetal hemoglobin is normal, but adult hemoglobin – produced after birth – is abnormal. Therefore, reversing their production of adult hemoglobin back to fetal hemoglobin can reverse the course of their disease.
In addition to the 100,000 US residents with SCD, the condition also affects millions globally. “I would remind people that anemia impacts 1.6 billion people worldwide, making it a global economic burden,” Dr. Blanc notes.
Dr. Blanc and his colleagues in the Division of Hematology/Oncology at Cohen Children’s Medical Center of New York plan to launch a clinical trial in the near future in collaboration with other institutions to test pomalidomide, which is taken orally, in young adults with SCD.
Currently, the only potential cures for SCD are gene therapy, still in the experimental stage, or stem cell transplant, but these resource-intense treatments aren’t available to the vast majority of patients, particularly in the developing world.
“Our hope is to alleviate the symptoms of sickle cell disease by using a pill that could be made available to almost all patients, worldwide,” Dr. Blanc said.
The Latest on: Sickle Cell Disease
via Google News
The Latest on: Sickle Cell Disease
- Novel Sickle Cell Disease Causes Radical Results In End Of Life Patientson November 30, 2019 at 6:41 am
This week the FDA approved a novel treatment for sickle cell disease, a serious and sometimes deadly disease that affects around 100,000 Americans. The treatment was found to exceptionally improve the ...
- FDA Approves Oxbryta for Treatment of Sickle Cell Diseaseon November 26, 2019 at 9:46 pm
TUESDAY, Nov. 26, 2019 (HealthDay News) -- Oxbryta (voxelotor) has been granted accelerated approval for the treatment of sickle cell disease in patients ages 12 years and older, the U.S. Food and ...
- A new Sickle cell disease drug holds much promise but most sufferers won’t be able to afford iton November 26, 2019 at 4:04 pm
The regulatory approval of a groundbreaking new Sickle cell disease drug in the United States by the Food and Drugs Administration (FDA) sparked off plenty of hope and optimism earlier this month and ...
- New Drugs Emerge to Treat Sickle Cell Diseaseon November 25, 2019 at 1:28 pm
The U.S. Food and Drug Administration approved a new drug for sickle cell disease Monday, adding to a new wave of treatments that promise relief from the life-threatening blood disorder that largely ...
- Global Blood secures FDA approval for new pill to treat sickle cell diseaseon November 25, 2019 at 1:16 pm
The Food and Drug Administration on Monday approved a once-daily pill for sickle cell disease that works in an entirely new way — by boosting hemoglobin, the oxygen-carrying molecule found in red ...
- FDA approves Global Blood Therapeutics sickle cell disease drugon November 25, 2019 at 12:56 pm
Nov 25 (Reuters) - The U.S. Food and Drug Administration said on Monday it approved a drug from Global Blood Therapeutics Inc to treat sickle cell disease in adults and children 12 years or older. © ...
- FDA approves Global Blood Therapeutics's sickle cell disease drugon November 25, 2019 at 12:56 pm
The U.S. Food and Drug Administration said on Monday it had approved Global Blood Therapeutics's drug, Oxbryta, to treat sickle cell disease in adults and pediatric patients aged 12 years or older.
- Global Blood Therapeutics scores FDA nod for Oxbryta, forecasts 'paradigm shift' in sickle cell diseaseon November 25, 2019 at 12:26 pm
Another day, another early FDA nod. Global Blood Therapeutics has its first drug approval, and it’s one that’ll bring a “paradigm shift” in how patients with sickle cell disease are treated, execs say ...
- FDA Approves Oxbryta(TM) (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Diseaseon November 25, 2019 at 12:03 pm
a new class of therapy Oxbryta broadly indicated for the treatment of sickle cell disease in adults and children 12 years of age and older1 Approval comes three months ahead of FDA's priority review ...
- Global Sickle Cell Disease Treatment Market 2019-2023| Evolving Opportunities with ADDMEDICA and Bristol-Myers Squibb | Technavioon November 22, 2019 at 4:01 pm
The global sickle cell disease treatment market is poised to grow by USD 1.85 billion during 2019-2023, progressing at a CAGR of over 11% during the forecast period. Request Free Sample Pages This ...
via Bing News